Postmenopausal hormone replacement therapy: Effects on normal mammary gland in humans and in a mouse postmenopausal model

Journal of Mammary Gland Biology and Neoplasia

Volumn 7, Issue 1, 2002, Pages 93-105

  Haslam, Sandra Z ^a   Osuch, Janet R ^b   Raafat, A M ^c   Hofseth, L J ^c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Estrogen; Hormone replacement therapy; Menopause; Progestin

Indexed keywords

ESTRADIOL; ESTROGEN; KI 67 ANTIGEN; PROGESTERONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER RISK; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; LONG TERM EXPOSURE; MAMMARY GLAND; MAMMOGRAPHY; MOUSE; NONHUMAN; POSTMENOPAUSE; PREMENOPAUSE; REVIEW; ANIMAL; ANIMAL MODEL; BREAST; BREAST TUMOR; DRUG EFFECT; EPITHELIUM; METABOLISM; PHYSIOLOGY; RISK FACTOR; UDDER;

ANIMALS; BREAST; BREAST NEOPLASMS; EPITHELIUM; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MAMMARY GLANDS, ANIMAL; MICE; MODELS, ANIMAL; POSTMENOPAUSE; PROGESTERONE; RISK FACTORS;

EID: 0036369960     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015726608146     Document Type: Review

References (79)

1. E. H. Lieberman, M. D. Gerhard, A. Uehata, B. W. Walsh, A. P. Selwyn, P. Ganz, A. C. Yeung, and M. A. Creager (1994). Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann. Intern. Med. 121:936-941.
2. P. Polo-Kantola, R. Erkkola, H. Helenius, K. Irjala, and O. Polo (1998). When does estrogen replacement therapy improve sleep quality? Am. J. Obstet. Gynecol. 178:1002-1009.
3. A. L. Kok, C. W. Burger, P. H. van de Weijer, G. A. Voetberg, E. R. Peters-Muller, and P. Kenemans (1999). Micturation complaints in postmenopausal women treated with continuously combined hormone replacement therapy: A prospective study. Maturitas 31:143-149.
4. L. A. Shimp and M. A. Smith (2000). Menopause. In M. A. Smith and L. A. Shimp (eds.). Women's Health Care, McGraw-Hill, New York, pp. 91-131.
5. T. A. Hutchinson, S. M. Polansky, and A. R. Feinstem (1979). Post-menopausal oestrogens protect against fractures of hip and distal radius. Lancet ii:705-709.
6. M. J. Stampfer, G. A. Colditz, W. C. Willett, J. E. Manson, B. Rosner, F. E. Speizer, and C. H. Hennekens (1991). Postmenopausal estrogen therapy and cardiovascular disease. N. Engl. J. Med. 325:756-762.
7. M.-X. Tang, D. Jacobs, Y. Stern, K. Marder, P. Schofield, B. Gurland, H. Andrews, and R. Mayeux (1996). Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348:429-432.
8. C. Rodriguez, A. V. Patel, E. E. Calle, E. J. Jacob, and M. J. Thun (2001). Estrogen replacement therapy and ovarian cancel-mortality in a large prospective study of U.S. women. JAMA 285:1460-1465.
9. E. Hoibraaten, E. Qvigstad, H. Arnesen, S. Larsen, E. Wickstrom, and P. M. Sandset (2000). Increased risk of recurrent venous thromboembolism during hormone replacement therapy - results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb. Haemost. 84:961-967.
10. D. M. Herrington, D. M. Reboussin, K. B. Brosnihan, P. C. Sharp, S. A. Shumaker, T. E. Snyder, C. D. Furberg, G. J. Kowalchuk, T. D. Stuckey, W. J. Rogers, D. H. Givens, and D. Waters (2000). Effects of estrogen replacement on the progression of coronary-artery athereosclerosis. N. Engl. J. Med. 343:522-529.
11. S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs, and E. Vittinghoff (1998). Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) research group. JAMA 280:605-613.
12. J. A. Blakely (2000). The Heart and Estrogen/Progestin Replacement Study revisited. Arch. Intern. Med. 160:2897-2900.
13. D. W. Cramer and R. C. Knapp (1979). Review of epidemiologic studies of endometrial cancer and exogenous estrogen. Obstet. Gynecol. 54:521-524.
14. I. Persson, H.-O. Adami, I. Bergkvist, A. Lindgren, B. Pettersson, R. Hoover, and C. Schairer (1989). Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: Results of a prospective study. Br. Med. J. 298:147-151.
15. L. A. Wallis and D. M. Barbo (1998). Hormone replacement therapy. In L. A. Wallis (ed.). Textbook of Women's Health. Lippincott-Raven, Philadelphia, p. 738.
16. R. D. Gambrell (1987). Use of progestogen therapy. Am. J. Obstet. Gynecol. 156:1304-1313.
17. M. Pike, D. Spicer, L. Dahmoush, and M. F. Press (1993). Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol. Rev. 15:17-35.
18. M. C. Pike, M. D. Krailo, B. E. Henderson, C. J. T. and D. G. Hoel (1983). "Hormonal" risk factors, "breast tissue age" and the age-incidence of breast cancer. Nature 303:767-770.
19. D. Trichopoulos, B. MacMahon, and P. Cole (1968). Menopause and breast cancer risk. J. Natl. Cancer Inst. 41:315-329.
20. R. A. Smith and R. G. Giusti (1997). The epidemiology of breast cancer. In L. W. Bassett, V. P. Jackson, R. Jahan, Y. S. Fu, and R. H. Gold (eds.), Diagnosis of Diseases of the Breast, W.B. Saunders, Philadelphia, pp. 293-316.
21. J. Russo and I. H. Russo (1995). The etiopathogenesis of breast cancer prevention. Cancer Lett. 90:81-89.
22. F. B. Wagner (1991). History of breast disease and its treatment. In K. I. Bland and E. M. Copeland (eds.). The Breast - Comprehensive Management of Benign and Malignant Diseases, W.B. Saunders, Philadelphia, pp. 1-16.
23. H. Olsson, H. Jernstrom, P. Alm, H. Kreipe, C. Ingvar, P. E. Jonsson, and S. Ryden (1996). Proliferation of the breat epithelium in relation to menstrual cycle phase, hormonal use, and reproductive factors. Breast Cancer Res. Treat. 40:187-196.
24. G. Soderqvist, E. Isaksson, B. von Schoultz, K. Carlstrom, E. Tani, and L. Skoog (1997). Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am. J. Obstet. Gynecol. 176:123-128.
25. C. M. Johansson, T. J. Anderson, R. Bergstrom, A. Lindgren, and I. R. Persson (1998). Epithelial proliferation in the normal human breast in relation to endogenous hormones and oral contraceptive use. The Breast 7.
26. M. B. Laya, J. C. Gallagher, J. S. Schreiman, E. B. Larson, P. Watson, and L. Weinstein (1995). Effect of postmenopausal hormone replacement therapy on mammographic density and parenchymal pattern. Radiology 196:433-437.
27. E. E. Sterns and B. Zee (2000). Mammographic density changes in perimenopausal and postmenopausal women: Is effect of hormone replacement therapy predictable? Breast Cancer Res. Treat. 59:125-132.
28. D. R. Peck and R. M. Lowman (1978). Estrogen and the postmenopausal breast: Mammographic considerations. JAMA 240:1733-1735.
29. P. C. Stomper, B. J. Van Voorhis, V. A. Ravnikar, and J. E. Meyer (1990). Mammographic changes associated with postmenopausal hormone replacement therapy: A longitudinal study. Radiology 174:487-490.
30. Z. Kaufman, W. I. Garstin, R. Hayes, M. J. Michell, and M. Baum (1991). The mammographic parenchymal patterms of women on hormone replacement therapy. Clin. Radiol. 43:389-392.
31. P. C. Stomper, D. J. D'Souza, P. A. DiNitto, and M. A. Arredondo (1996). Analysis of parenchymal density on mammograms in 1353 women 25-79 years old. Am. J. Roentgenol. 167:1261-1265.
32. C. T. Erel, H. Seyisoglu, M. L. Senturk, C. Akman, G. Ersavasti, A. Benian, C. Uras, A. Altug, and E. Ertungealp (1996). Mammographic changes in women on hormonal replacement therapy. Maturitas 25:51-57.
33. W. Leung, F. Goldberg, B. Zee, and E. Sterns (1997). Mammographic density in women on postmenopausal hormone replacement therapy. Surgery 122:669-673.
34. R. C. Marugg, M. J. van der Mooren, J. H. Hendriks, R. Rolland, and S. H. Ruijs (1997). Mammographic changes in postmenopausal women on hormone replacement therapy. Eur. Radiol. 7:749-755.
35. I. Persson, E. Thurfjell, and L. Holmberg (1997). Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchmal density. J. Clin. Oncol. 15:3201-3207.
36. E. Lundstrom, B. Wilczek, Z. von Palffy, G. Soderqvist, and B. von Schoultz (1999). Mammographic breast density during hormone replacement therapy: Differences according to treatment. Am. J. Obstet. Gynecol. 181:348-352.
37. R. C. Marugg, M. J. van der Mooren, J. H. Hendriks, R. Rolland, and S. H. Ruijs (1997). Mammographic changes in postmenopausal women on hormonal replacement therapy. Eur. Radiol. 7:749-755.
38. G. A. Greendale, B. A. Reboussin, A. Sie, H. R. Singh, L. K. Olson, O. Gatewood, L. W. Bassett, C. Wasilauskas, T. Bush, and E. Barrett-Connor (1999). Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) investigators. Ann. Intern. Med. 130:262-269.
39. C. M. Rutter, M. T. Mandelson, M. B. Laya, D. J. Seger, and S. Taplin (2001). Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 285:171-176.
40. A. F. Saftlas and M. Szklo (1987). Mammographic parenchymal patterns and breast cancer risk. Epidemiol Rev. 9:146-174.
41. E. Warner, G. Loockwood, D. Tritchler, and N. F. Boyd (1992). The risk of breast cancer associated with mammographic parenchymal patterns: A meta-analysis of the published literature to examine the effect of method of classification. Cancer Det. Prev. 16:67-72.
42. A. M. Oza and N. F. Boyd (1993). Mammographic parenchymal patterns: A marker of breast cancer risk. Epidemiol. Rev. 15:196-208.
43. J. S. Pankow, C. M. Vachon, C. C. Kuni, R. A. King, D. K. Arnett, D. M. Grabrick, S. S. Rich, V. E. Anderson, and T. A. Sellers (1997). Genetic analysis of mammographic breast density in adult women: Evidence of a gene effect. J. Natl. Cancer Inst. 89:549-556.
44. L. J. Hofseth, A. M. Raafat, J. R. Osuch, D. R. Pathak, C. A. Slomski, and S. Z. Haslam (1999). Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J. Clin. Endocrinol. Metab. 84:4559-4565.
45. D. F. Hargreaves, F. Knox, R. Swindell, C. S. Potten, and N. J. Bundred (1998). Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy. B. J. Cancer 78:945-949.
46. M. D. Cahn, T. Tran, C. P. Theur, and J. A. Butler (1997). Hormone replacement therapy and the risk of breast lesions that predispose to cancer. Am. Surg. 63:858-860.
47. T. E. Rohan and A. B. Miller (1999). Hormone replacement therapy and risk of benign proliferative epithelial disorders of the breast. Eur. J. Cancer Prev. 8:123-130.
48. G. A. Colditz and B. Rosner (1998). Use of estrogen plus progestin is associated with greater increase in breast cancer risk than estrogen alone. Am. J. Epidemiol. 147 (Suppl.):64S.
49. K. K. Steinberg, S. B. Thaker, S. J. Smith, D. F. Stroup, M. M. Zack, W. D. Flanders, and R. L. Berkelman (1991). A metaanalysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 265:1985-1990.
50. K. K. Steinberg, S. J. Smith, S. B. Thacker, and D. F. Stroup (1994). Breast cancer risk and duration of estrogen use: The role of study design in meta-analysis. Epidemiology 5:415-421.
51. Early Breast Trialists' Collaborative Group (1997). Breast cancer and hormone replacement therapy. Combined reanalysis of data from 51 epidemiologic studies involving 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1947-1059.
52. L. E. Nachtigall, R. H. Nachtigall, R. D. Nachtigall, and E. M. Beckman (1979). Estrogen replacement therapy. II. A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet. Gynecol. 54:74-79.
53. R. D. Gambrell, R. C. Maier, and B. I. Sanders (1983). Decreased incidence of breast cancer in post menopausal estrogen-progestogen users. Obstet. Gynecol. 62:435-443.
54. J. L. Stanford and D. B. Thomas (1993). Exogenous progestins and breast cancer. Epidemiol. Rev. 15:98-107.
55. G. A. Colditz, S. E. Sankinson, D. J. Hunter, W. C. Willett, J. E. Manson, M. J. Stampfer, C. Hennekens, B. Rosner, and F. E. Speizer (1995). The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 332:1589-93.
56. R. Sitruk-Ware (1992). Estrogens, progestins and breast cancer risk in post-menopausal women: State of the ongoing controversey in 1992. Maturitas 15:129-139.
57. D. A. Bell, S. I. Hajdu, J. A. Urban, and J. P. Gaston (1983). Role of aspiration cytology in the diagnosis and management of mammary lesions in office practice. Cancer 51:1882.
58. I. Persson, J. Yuen, L. Bergkvist, H.-O. Adami, R. Hoover, and C. Schairer (1992). Combined oestrogen-progestogen replacement and breast cancer risk. Lancet 340:1044.
59. I. Persson, E. Weiderpass, L. Bergkvist, R. Bergstrom, and C. Schairer (1999). Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 10:253-260.
60. C. Magnusson, J. A. Baron, N. Correia, R. Bergstrom, H. O. Adami, and I. Persson (1999). Breast-cancer risk following long-term oestrogen-and oestrogen-progestin-replacement therapy. Int. J. Cancer 81:339-344.
61. C. Schairer, J. Lubin, R. Troisi, S. Sturgeon, L. Brinton, and R. Hoover (2000). Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk [see comments]. JAMA 283:485-491.
62. R. K. Ross, A. Paganini-Hill, P. C. Wan, and M. C. Pike (2000). Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin [see comments]. J. Natl. Cancer Inst. 92:328-332.
63. T. B. L. Kirkwood (1985). Comparative and evolutionary aspects of longevity. Van Nostrand-Reinhold, New York.
64. J. M. Cline, G. Soderqvist, E. Schoultz, L. Skoog, and B. Schoultz (1996). Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am. J. Obstet. Gynecol 174:93-100.
65. M. C. Neville and C. W. Daniel (1987). The Mammary Gland: Development, Regulation and Function, Plenum, New York.
66. A. M. Raafat, L. J. Hofseth, S. Li, J. M. Bennett, and S. Z. Haslam (1999). A mouse model to study the effects of hormone replacement therapy on normal mammary gland during menopause: Enhanced proliferative response to estrogen in late postmenopausal mice. Endocrinology 140:2570-2580.
67. S. Z. Haslam (1989). The ontogeny of mouse mammary gland responsiveness to ovarian steroid hormones. Endocrinology 125:2766-2772.
68. S. Saji, E. V. Jensen, S. Nilsson, T. Rylander, M. Warner, and J. A. Gustafsson (2000). Estrogen receptors alpha and beta in the rodent mammary gland. Proc. Natl. Acad. Sci. U.S.A. 97:337-342.
69. L. Speroff, R. H. Glass, and N. G. Kase (1989). The ovary from conception to senescence. In C. L. Brown (ed.), Clinical Gynecologic Endocrinology and Infertility, Williams & Wilkins, Baltimore, pp. 121-163.
70. M. E. Lippman and J. C. Allegra (1980). Quantitative estrogen receptor analysis: The response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer 46:2829-2834.
71. A. M. Raafat, L. J. Hofseth, and S. Z. Haslam (2001). A mouse model to study the proliferative effects of hormone replacement therapy on normal postmenopausal mammary gland: Proliferative effects of combined estrogen and progestin treatment. Am. J. Obstet. Gynecol. 184:340-349.
72. I. Russo and J. Russo (1998). Role of hormones in mammary cancer initiation and progression. J. Mammary Gland. Biol. Neopl. 3:49-61.
73. C. Van-Gils, J. Otten, A. Verbeek, and J. Hendricks (1995). Short communication: Breast parenchymal patterns and their changes with age. Br. J. Radiol. 23:1133-1135.
74. J. Russo, R. Rivera, and I. H. Russo (1992). Influence of age and parity on development of the human breast. Breast Cancer Res. Treat. 23:211-218.
75. J. Russo and I. H. Russo (1997). Role of hormones in human breast development: The menopausal breast. In B. G. Wren (ed.), Progress in the Management of Menopause, Pathenon, London, pp. 184-193.
76. J. Russo and I. H. Russo (1996). Experimentally-induced mammary tumors in rats. Breast Cancer Res. Treat. 39:7-20.
77. D. Ras and B. K. Vonderhaar (1997). Prolactin as a mitogen in mammary cells. J. Mammary Gland Biol. Neopl. 2:29-39.
78. S. Z. Haslam (1988). Local vs. systemically mediated effects of estrogen on normal mammary epithelial cell DNA synthesis. Endocrinology 122:860-867.
79. A. M. Raafat, S. Li, J. M. Bennett, L. J. Hofseth, and S. Z. Haslam (2001). Estrogen and estrogen plus progestin act directly on the mammary gland to increase proliferation in a postmenopausal mouse model. J. Cell. Physiol. 187:81-89.